Management of atrial fibrillation

Vascular Health and Risk Management

Volumn 3, Issue 1, 2007, Pages 109-116

  Kakar, Puneet ^a   Boos, Christopher J ^a,b   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b FASC   (United Kingdom)

Author keywords

Atrial fibrillation; Guidelines; National Institute of Clinical Excellence

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIGOXIN; FLECAINIDE; HEPARIN; PLACEBO; SOTALOL; WARFARIN;

CLINICAL TRIAL; DISEASE COURSE; EVIDENCE BASED PRACTICE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; MORBIDITY; MORTALITY; PATIENT CARE; PRACTICE GUIDELINE; RESOURCE ALLOCATION; REVIEW; STROKE; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HEART RATE; HUMANS; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 34249888520     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Alboni P, Botto GL, Baldi NL, et al. 2004. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Eng J Med, 351:2384-91.
2. Almassi GH, Schowalter T, Nicolosi AC, et al. 1997. Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg, 226:501-11.
3. Antonielli E, Pizzuti A, Palinkas A, et al. Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol, 39:1443-9.
4. Aronow WS, Ahn C, Kronzon I, et al. 1998. Risk factors for new thromboembolic stroke in patients≥62 years of age with chronic atrial fibrillation. Am J Cardiol, 82:119-21.
5. Benavente O, Hart F, Koudstaal P, et al. 2003. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. The Cochrane Library.
6. Benjamin EJ, Levy D, Vaziri SM, et al. 1994. Independent risk factors for atrial fibrillation in a population based cohort: the Framingham heart study. J Am Med Assoc, 271:840-4.
7. Benjamin EJ, Wolf PA, D'Agostino RB, et al. 1998. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation, 98:946-52.
8. Bungard TJ, Ghali WA, Teo KK, et al. 2000. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med, 160:41-6.
9. Burton JH, Vinson DR, Drummond K, et al. 2004. Electrical cardioversion of emergency department patients with atrial fibrillation. Ann Emerg Med, 44:20-30.
10. Carlsson J, Miketic S, Windeler JS, et al. 2003. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the strategies of treatment of atrial fibrillation (STAF) Study. J Am Coll Cardiol, 41:1690-6.
11. Collins LJ, Silverman DI, Douglas PS et al. 1995. Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related toatrial thrombus resolution. Circulation, 92:160-3.
12. Corley SD, Epstein AE, DiMarco JP, et al. 2004 Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation, 109:1509-13.
13. Crystal E, Connolly SJ, Ginger T, et al. 2003. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. The Cochrane Library.
14. David D, Di Segni E, Klein HO, Kaplinsky E, et al. 1979. Inefficiency of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effects of an added beta-adrenergic blocking agent. Am J Cardiol, 44:1378-1382.
15. Dmochowska-Perz M, Loboz-Grudzien K, Sokalski L, et al. 2002. Factors predicting recurrence of atrial fibrillation after cardioversion. Kardiologia Polska, 57:501-11.
16. Dogan A, Avsar A, Ozturk M, et al. 2004 P-wave dispersion for predicting maintenance of sinus rhythm after cardioversion of atrial fibrillation. Am J Cardiol, 93:368-71.
17. Evans A, Perez I, Yu G, Kalra L. 2001. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke, 32:2828-32.
18. [EAFT] European Atrial Fibrillation Study Group. 1993. Secondary prevention in non rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet, 342:1255-62.
19. Ezekowitz MD, Laupacis A, Boysen G, et al. 1998. Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials. Arch Intern Med, 158:1316-20.
20. Fang MC, Stafford RS, Ruskin JN, et al. 2004. National trends in anti-arryhthmic and anti-thrombotic medication use in atrial fibrillation. Arch Intern Med, 164:55-60.
21. Farshi R, Kistner D, Sarnia JS, et al. 1999. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol, 33:304-10.
22. Fitzmaurice DA, Murray ET, McCahon D et al. 2005. Self management of oral anticoagulation: randomised trial. BMJ, 331:1057.
23. Freestone B, Lip GYH. 2003. Epidemiology and costs of Cardiac Arrhythmias. In: Lip GYH, Godtfredson J, eds. Cardiac arryhythmias: a clinical approach. Edinburgh: Mosby. pp 3-24.
24. Frick M, Frykman V, Jensen-Urstad M, et al. 2001. Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol, 24:238-44.
25. Galperin J, Elizari MV, Chiale PA, et al. 2003. Pharmacologic reversion of persistent atrial fibrillation with amiodarone predicts long-term sinus rhythm maintenance. J Cardiovas Pharmacol Ther, 8:179-86.
26. Fuster V, Ryden LE, Asinger RW, et al. 2001. American College of Cardiology/American Heart Association/European Society of Cardiology Board. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary a report of the American College of Cardiology/American heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation, 104:2118.
27. Fuster V, Rydén L.E, David S, et al. 2006. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With atrial fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation, 114:e257-e354.
28. Gage BF, Waterman AD, Shannon W, et al. 2001. Validation of clinical classification schemes for predicting stroke: results from the National Registry of atrial fibrillation. JAMA, 285:2864-2870.
29. Go AS, Hylek EM, Phillips KA. 2001. Prevalence of diagnosed atrial fibrillation in adults, national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA, 285:2370-5.
30. Gronefeld GC, Lilienthal J, Kuck KH, et al. 2003. Pharmacological intervention in atrial fibrillation. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. iEur Heart J, 24:1430-6.
31. Hart RG, Benavente O, McBride R, et al. 1999. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann intern Med, 131:492-501.
32. Hart RG, Pearce LA, Rothbart RM, et al. 2000. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol, 35:183-7.
33. Hohnloser SH, Kuck KH. 2001. Randomized trial of rhythm or rate control in atrial fibrillation: the Pharmacological intervention in atrial fibrillation trial (PIAF). Eur Heart J, 22:801-2.
34. Kamp O, Verhorst PMJ, Welling RC, et al. 1999. Importance of left atrial appendage flow as a predictor of thromboembolic events in patients with atrial fibrillation. Eur Heart J, 20:979-85.
35. Kawaguchi AT, Kosakai Y, Sasako Y, et al. 1996. Risks and benefits of combined maze procedure for atrial fibrillation associated with organic heart disease. J Am Coll Cardiol, 28:985-90.
36. Kinlay S, Leitch JW, Neil A, et al. 1996. Cardiac event recorders yield more diagnoses and are more cost-effective than 48-hour Holter monitoring in patients with palpitations. A controlled clinical trial. Ann Inter Med, 124:16-20.
37. Klein AL, Grimm RA, Murray RD, et al. 2001. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med, 344:1411-20.
38. Kochiadakis GE, Igoumenidis NE, Hamilos MI, et al. 2004. Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. Chest, 125:377-83.
39. Lardoux H, Mallet A, et al. 2001. FFAACS (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane) Investigators. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane, FFAACS). Cerebrovasc Dis, 12:245-52.
40. Lee JK, Klein GJ, Krahn AD, et al. 2003. Rate-control versus conversion strategy in postoperative atrial fibrillation: trial design and pilot study results. Card Electrophysiol Rev, 7:178-84.
41. Levy T, Walker S, Rochelle J, et al. 1999. Evaluation of biatrial pacing, right atrial pacing, and no pacing in patients with drug refractory atrial fibrillation. Am J Cardiol, 84:426-9.
42. Li-Saw-Hee FL, Lip GYH. 1998. Digoxin Revisted. Q JM, 91:259-64.
43. Lim HS, Hamaad A, Lip GY 2004. Clinical management of atrial fibrillation - rate control versus rhythm control. Crit Care, 8:271-9.
44. Lin HJ, Wolf PA, Kelly-Hayes M, et al. 1996. Stroke severity in atrial fibrillation: the Framingham study. Stroke, 27: 1760-4
45. Lip GY, Edwards SJ. 2006. Stroke prevention with aspirin, warfarin and ximelgatran in patients with atrial fibrillation: a systematic review and meta-analysis. Thromb Res, 118:321-33.
46. Lip GY, Boos CJ. 2005. Antithrombotic therapy for atrial fibrillation. Heart, 92:155-61.
47. Lip GY, Tean KN, Dunn FG. 1994. Treatment of atrial fibrillation in a district general hospital. Br Heart J, 71:92-5.
48. Lip GY. 1995. Does atrial fibrillation confer a hypercoagulable state? Lancet, 346:1313-14.
49. Lip GY, Lane D, Van Walraven C, et al. 2006. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke, 37:2294-300.
50. Maragno I, Santostasi G, Gaion RM, et al. 1998. Low- and medium-dose diltiazeni in chronic atrial fibrillation: comparison with digoxin and correlation with drug plasma levels. Am Heart J, 116:385-92.
51. Michael JA, Stiell IG, Agarwal S, et al. 1999. Cardioversion of paroxysmal atrial fibrillation in the emergency department. Ann Emerge Med, 33:379-87.
52. Miyazaki S, Ito T, Suwa M, et al. 2001. Role of transesophageal echocardiography in the prediction of thromboembolism in patients with chronic nonvalvular atrial fibrillation. Jpn Circ J, 65:874-8.
53. Morgan S, Mant D. 2002. Randomised trial of two approaches to screening for atrial fibrillation in UK generalpractice. Br J Gen Pract, 52:373-80.
54. Murray ET, Fitzmaurice DA, McCahon D. 2004. Point of care testing for INR monitoring: where are we now? Br J Haematol, 127:373-8.
55. Okcun B, Yigit Z, Arat A, 2004. Comparison of rate and rhythm control in patients with atrial fibrillation and nonischemic heart failure. Jpn Heart J, 45:591-601.
56. Okcun B, Yigit Z, Kucukoglu MS, et al. 2002. Predictors for maintenance of sinus rhythm after cardioversion in patients with nonvalvular atrial fibrillation. Echocardiography, 19:351-7.
57. Opolski G, Torbicki A, Kosior D, et al. 2003. Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study. Kardiologia Polska, 59:1-16.
58. Page RL, Wilkinson WE, Clair WK, et al. 1994. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation, 89:224-7.
59. Paraskevaidis IA, Dodouras T, Tsiapras D. 2005. Prediction of successful cardioversion and maintenance of sinus rhythm in patients with lone atrial fibrillation. Chest, 127:488-94.
60. Reiffel JA, Schwarzberg R, Murry M. 2005. Comparison of autotriggered memory loop recorders versus standard loop recorders versus 24-hour holter monitors for arrhythmia detection. Am J Cardiol, 95:1055-9.
61. Ricci R, Quesada A, Pignalberi C, et al. 2004. Dual defibrillator improves quality of life and decreases hospitalizations in patients with drug refractory atrial fibrillation. J Interv Card Electrophysiol, 10:85-92.
62. Roijer A, Meurling CJ, Eskilsson J, et al. 2001. Left atrial appendage outflow velocity index is superior to conventional criteria for prediction of maintenance of sinus rhythm after cardioversion. Scand Cardiovas J, 35:119-24.
63. Roy D, Talajic M, Dorian P, et al. 2000. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of atrial fibrillation investigators. N Engl J Med, 342:913-20.
64. Seitelberger R, Hannes W, Gleichauf M, et al. 1994. Effects of diltiazem on perioperative ischemia, arrhythmias, and myocardial function in patients undergoing elective coronary bypass grafting. J Thorac Cardiovasc Surg, 107:811-21.
65. Shinokawa N, Hirai T, Takashima S, et al. 2001. A transesophageal echocardiographic study on risk factors for stroke in elderly patients with atrial fibrillation: a comparison with younger patients. Chest, 120:840-6.
66. Singer DE, Albers GW, Dalen JE, et al. 2004. Antithrombotic Therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126:429S-56S.
67. Stroke Prevention in atrial fibrillation investigators. 1991. The Stroke Prevention in atrial fibrillation (SPAF) study: final results. Circulation, 84:527-539.
68. Steeds RP, Birchall AS, Smith M, et al. 1999. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart, 82:170-5.
69. Strasberg B, Arditti A, Sclarovsky S. 1985. Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response. Int J Cardiol, 7:47-55.
70. Stewart S, Hart CL, Hole DJ, et al. 2001. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart, 86:516-21.
71. Swancutt D, Hobbs R, Fitzmaurice D, et al. 2004. A randomised controlled trial and cost effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in the over 65s: (SAFE). BMC Cardiovasc Disord, 4:12.
72. Sudlow M, Rodgers H, Kenny RA, et al. 1998. Identification of patients with atrial fibrillation in generalpractice: a study of screening methods. BMJ, 317:327-8.
73. Ueng KC, Tsai TP, Tsai CF, et al. 2001. Acute and long-term effects of atrioventricular junction ablation and VVIR pacemaker in symptomatic patients with chronic lone atrial fibrillation and normal ventricular response. J Cardiovasc Electrophysiol, 12:303-9.
74. Valencia MJ, Climent PV, Marin O, et al. 2002. The efficacy of scheduled cardioversion in atrial fibrillation: Comparison of two schemes of treatment: Electrical versus pharmacological cardioversion. Revista Espanola de Cardiologia, 55:113-20.
75. van Walraven C, Hart RG, Singer DE, et al. 2002. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient metaanalysis. JAMA, 288:2441-8.
76. van Walraven C, Hart RG, Wells GA, et al. 2003. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med, 163:936-43.
77. Van Gelder IC, Hagens VE, Bosker HA, et al. 2002. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med, 347:1834-40.
78. Vecht RJ, Nicolaides EP, Ikweuke JK. 1986. Incidence and prevention of supraventricular tachyarrhythmias after coronary bypass surgery. Int J Cardiol, 13:125-34. Wang HE, O'connor RE, Megargel RE, et al. 2001. The use of diltiazem-for treating rapid atrial fibrillation in the out-of-hospital setting. Ann Emerge Med, 37:38-45.
79. Wazni OM, Marrouche NF, Martin DO, et al. 2005. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: A randomized trial. JAMA, 293:2634-40.
80. Wolf PA, Benjamin EJ, Belanger AJ, et al. 1996. Secular trends in the prevalence of atrial fibrillation: the Framingham study. Am Heart J, 131:790-5.
81. Wolf PA, Belanger AJ, Kannel WB, et al. 1991. Probabilty of stroke: A risk profile ftom Framingham study. Stroke, 22:312-8.
82. Wolf PA, Kannel WB, McGee DL, et al. 1983. Duration of atrial fibrillation and imminence of stroke: the Framingham study. Stroke, 14:664-7.
83. Wyse DG, Waldo AL, DiMarco JP, et al. 2002. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med, 347:1825-33.
84. Zarifis J, Beevers G, Lip GY. 1997. Acute admissions with atrial fibrillation in a British multiracial hospital population. Br J Clin Pract, 51:91-6.